Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Laubach

Showing results (11-20 of 82) with videos related to

Pageof 9
Sort By:
Blood|February 2, 2013
Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapyPeter M Voorhees, Jacob Laubach, Kenneth C Anderson, et al.
Oncology (Williston Park, N.Y.)|October 19, 2013
IgD and IgE variants of myeloma: valuable insights and therapeutic opportunitiesPaul G Richardson, Jacob Laubach, Claudia Paba-Prada, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2021
Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based systemAric Parnes, Houry Leblebjian, Joanna Hamilton, et al.
Nature Reviews. Clinical Oncology|February 22, 2012
Latest advances and current challenges in the treatment of multiple myelomaAnuj Mahindra, Jacob Laubach, Noopur Raje, et al.
Expert Opinion on Biological Therapy|August 18, 2016
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myelomaSagar Lonial, Jonathan Kaufman, Donna Reece, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 20, 2018
Evaluating the adverse effects of melphalan formulationsElaine Xiang, Jian Ni, Brett Glotzbecker, et al.
Expert Review of Anticancer Therapy|June 23, 2018
Maintenance and continuous therapy for multiple myelomaPaul G Richardson, Jacob Laubach, Sara Gandolfi, et al.
Seminars in Oncology|October 19, 2013
Evolving strategies in the initial treatment of multiple myelomaCara Rosenbaum, Jagoda Jasielec, Jacob Laubach, et al.
Hematology/Oncology Clinics of North America|September 13, 2014
Novel targeted agents in the treatment of multiple myelomaCindy Varga, Jacob Laubach, Teru Hideshima, et al.
British Journal of Haematology|May 15, 2014
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myelomaMin Jung Lee, Paige Wickner, Laura Fanning, et al.
Pageof 9

Showing results (11-20 of 82) with videos related to

Sort By:
Pageof 9
Blood|February 2, 2013
Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapyPeter M Voorhees, Jacob Laubach, Kenneth C Anderson, et al.
Oncology (Williston Park, N.Y.)|October 19, 2013
IgD and IgE variants of myeloma: valuable insights and therapeutic opportunitiesPaul G Richardson, Jacob Laubach, Claudia Paba-Prada, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 22, 2021
Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based systemAric Parnes, Houry Leblebjian, Joanna Hamilton, et al.
Nature Reviews. Clinical Oncology|February 22, 2012
Latest advances and current challenges in the treatment of multiple myelomaAnuj Mahindra, Jacob Laubach, Noopur Raje, et al.
Expert Opinion on Biological Therapy|August 18, 2016
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myelomaSagar Lonial, Jonathan Kaufman, Donna Reece, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 20, 2018
Evaluating the adverse effects of melphalan formulationsElaine Xiang, Jian Ni, Brett Glotzbecker, et al.
Expert Review of Anticancer Therapy|June 23, 2018
Maintenance and continuous therapy for multiple myelomaPaul G Richardson, Jacob Laubach, Sara Gandolfi, et al.
Seminars in Oncology|October 19, 2013
Evolving strategies in the initial treatment of multiple myelomaCara Rosenbaum, Jagoda Jasielec, Jacob Laubach, et al.
Hematology/Oncology Clinics of North America|September 13, 2014
Novel targeted agents in the treatment of multiple myelomaCindy Varga, Jacob Laubach, Teru Hideshima, et al.
British Journal of Haematology|May 15, 2014
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myelomaMin Jung Lee, Paige Wickner, Laura Fanning, et al.
Pageof 9